Differential oestrogen receptor binding is associated with clinical outcome in breast cancer CS Ross-Innes, R Stark, AE Teschendorff, KA Holmes, HR Ali, ... Nature 481 (7381), 389-393, 2012 | 2028 | 2012 |
RNA sequencing: the teenage years R Stark, M Grzelak, J Hadfield Nature Reviews Genetics 20 (11), 631-656, 2019 | 1667 | 2019 |
Progesterone receptor modulates ERα action in breast cancer H Mohammed, IA Russell, R Stark, OM Rueda, TE Hickey, GA Tarulli, ... Nature 523 (7560), 313-317, 2015 | 747 | 2015 |
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis CE Massie, A Lynch, A Ramos‐Montoya, J Boren, R Stark, L Fazli, ... The EMBO journal 30 (13), 2719-2733, 2011 | 697 | 2011 |
DiffBind: differential binding analysis of ChIP-Seq peak data R Stark, G Brown R package version 100 (4.3), 2011 | 647 | 2011 |
Piwi and piRNAs act upstream of an endogenous siRNA pathway to suppress Tc3 transposon mobility in the Caenorhabditis elegans germline PP Das, MP Bagijn, LD Goldstein, JR Woolford, NJ Lehrbach, ... Molecular cell 31 (1), 79-90, 2008 | 492 | 2008 |
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man NL Sharma, CE Massie, A Ramos-Montoya, V Zecchini, HE Scott, ... Cancer cell 23 (1), 35-47, 2013 | 431 | 2013 |
GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility V Theodorou, R Stark, S Menon, JS Carroll Genome research 23 (1), 12-22, 2013 | 390 | 2013 |
Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation T Chandra, K Kirschner, JY Thuret, BD Pope, T Ryba, S Newman, ... Molecular cell 47 (2), 203-214, 2012 | 306 | 2012 |
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study H Ross-Adams, AD Lamb, MJ Dunning, S Halim, J Lindberg, CM Massie, ... EBioMedicine 2 (9), 1133-1144, 2015 | 287 | 2015 |
Cooperative interaction between retinoic acid receptor-α and estrogen receptor in breast cancer CS Ross-Innes, R Stark, KA Holmes, D Schmidt, C Spyrou, R Russell, ... Genes & development 24 (2), 171-182, 2010 | 283 | 2010 |
Impact of artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data TS Carroll, Z Liang, R Salama, R Stark, I de Santiago Frontiers in genetics 5, 75, 2014 | 239 | 2014 |
BayesPeak: Bayesian analysis of ChIP-seq data C Spyrou, R Stark, AG Lynch, S Tavaré BMC bioinformatics 10, 1-17, 2009 | 163 | 2009 |
5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer S Uribe-Lewis, R Stark, T Carroll, MJ Dunning, M Bachman, Y Ito, L Stojic, ... Genome biology 16, 1-15, 2015 | 84 | 2015 |
Latent regulatory potential of human-specific repetitive elements MC Ward, MD Wilson, NL Barbosa-Morais, D Schmidt, R Stark, Q Pan, ... Molecular cell 49 (2), 262-272, 2013 | 78 | 2013 |
Nuclear ARRB 1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer V Zecchini, B Madhu, R Russell, N Pértega‐Gomes, A Warren, E Gaude, ... The EMBO journal 33 (12), 1365-1382, 2014 | 69 | 2014 |
DiffBind: differential binding analysis of ChIP-Seq peak data. Bioconductor R Stark, G Brown DiffBind: differential binding analysis of ChIP-Seq peak data: Bioconductor, 2011 | 66 | 2011 |
BayesPeak—an R package for analysing ChIP-seq data J Cairns, C Spyrou, R Stark, ML Smith, AG Lynch, S Tavaré Bioinformatics 27 (5), 713-714, 2011 | 54 | 2011 |
Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target M Asim, CE Massie, F Orafidiya, N Pértega-Gomes, AY Warren, ... Journal of the National Cancer Institute 108 (5), djv371, 2016 | 53 | 2016 |
ZFTA Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors R Kupp, L Ruff, S Terranova, E Nathan, S Ballereau, R Stark, ... Cancer discovery 11 (9), 2216-2229, 2021 | 44 | 2021 |